Sorafenib (BioDeep_00000614815)

   


代谢物信息卡片


Sorafenib

化学式: C21H16ClF3N4O3 (464.0862972)
中文名称: 索拉非尼
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
InChI: InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)

描述信息

C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor
C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor > C93259 - VEGFR Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163953 - VEGFR-targeting Agent
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C164037 - PDGFR-targeting Agent
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2336 - Raf Kinase Inhibitor
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
D000970 - Antineoplastic Agents
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
Sorafenib (Bay 43-9006) is a potent and orally active Raf inhibitor with IC50s of 6 nM and 20 nM for Raf-1 and B-Raf, respectively. Sorafenib is a multikinase inhibitor with IC50s of 90 nM, 15 nM, 20 nM, 57 nM and 58 nM for VEGFR2, VEGFR3, PDGFRβ, FLT3 and c-Kit, respectively. Sorafenib induces autophagy and apoptosis. Sorafenib has anti-tumor activity. Sorafenib is a ferroptosis activator[1].

同义名列表

2 个代谢物同义名

Sorafenib; Bay 43-9006



数据库引用编号

10 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(11)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Jinrui Wei, Xuqi Zhao, Fuli Long, Kunpeng Tian, Lichuan Wu. Lianhua Qingwen exerts anti-liver cancer effects and synergistic efficacy with sorafenib through PI3K/AKT pathway: Integrating network pharmacology, molecular docking, and experimental validation. Gene. 2024 Jun; 912(?):148383. doi: 10.1016/j.gene.2024.148383. [PMID: 38493972]
  • Yiting Hu, Zhongfei Luo, Siyi Cai, Qinfen Xie, Shusen Zheng. Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma. Scandinavian journal of gastroenterology. 2024 Jun; 59(6):730-736. doi: 10.1080/00365521.2024.2315317. [PMID: 38426342]
  • Jiarui Li, Yilan Li, Denghui Wang, Rui Liao, Zhongjun Wu. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma. Journal of experimental & clinical cancer research : CR. 2024 May; 43(1):143. doi: 10.1186/s13046-024-03061-4. [PMID: 38745179]
  • Rongliang Tong, Xiaode Feng, Jingqi Sun, Zhenan Ling, Jun Wang, Shun Li, Beng Yang, Junfang Deng, Guijin He, Jian Wu. Co-Delivery of siNRF2 and Sorafenib by a 'Click' Dual Functioned Hyperbranched Nanocarrier for Synergistically Inducing Ferroptosis in Hepatocellular Carcinoma. Small (Weinheim an der Bergstrasse, Germany). 2024 May; 20(21):e2307273. doi: 10.1002/smll.202307273. [PMID: 38102096]
  • Jing Yang, Wei Xiong, Lin Huang, Zongheng Li, Qingdeng Fan, Fang Hu, Xiaopin Duan, Junbing Fan, Bo Li, Jie Feng, Yikai Xu, Xiaoyuan Chen, Zheyu Shen. A mesoporous superparamagnetic iron oxide nanoparticle as a generic drug delivery system for tumor ferroptosis therapy. Journal of nanobiotechnology. 2024 Apr; 22(1):204. doi: 10.1186/s12951-024-02457-w. [PMID: 38658948]
  • Jing Zhao, Dongming Yan, Yue Li, Xiaoqing Xu, Fengling Li, Shuang Zhang, Jingyi Jin, Furong Qiu. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2024 Apr; 1237(?):124100. doi: 10.1016/j.jchromb.2024.124100. [PMID: 38547701]
  • Jie Ji, Ziqi Cheng, Jie Zhang, Jianye Wu, Xuanfu Xu, Chuanyong Guo, Jiao Feng. Dihydroartemisinin induces ferroptosis of hepatocellular carcinoma via inhibiting ATF4-xCT pathway. Journal of cellular and molecular medicine. 2024 Apr; 28(8):e18335. doi: 10.1111/jcmm.18335. [PMID: 38652216]
  • Kangli Xue, Rui Yang, Yanli An, Yinan Ding, Su Li, Fengqin Miao, Dongfang Liu, Daozhen Chen, Qiusha Tang. NIR-promoted ferrous ion regeneration enhances ferroptosis for glioblastoma treatment. Journal of controlled release : official journal of the Controlled Release Society. 2024 Apr; 368(?):595-606. doi: 10.1016/j.jconrel.2024.01.004. [PMID: 38185333]
  • Jia-Heng Xing, Ru-Xue Tan, Fei-Er Huang, Nan Tian. Integrated analyses for identification of a three-gene signature associated with Chaihu Shugan San formula for hepatocellular carcinoma treatment. Journal of cellular and molecular medicine. 2024 Apr; 28(8):e18211. doi: 10.1111/jcmm.18211. [PMID: 38613352]
  • Yanan Chen, Zhonghao Jiang, Zhuo Yan, Jierong Liu, Yilin Lai, Li Li, Xiao Lin, Jiantao Lin. A codelivery system loaded with PDL1-siRNA and sorafenib enhances the therapeutic effect of sorafenib on hepatocellular carcinoma via TAT-poly-SS-lysine modified chitosan. International journal of biological macromolecules. 2024 Apr; 263(Pt 1):130162. doi: 10.1016/j.ijbiomac.2024.130162. [PMID: 38365149]
  • Ran Guo, Fang Lu, Jiang Lin, Caixia Fu, Mengxiao Liu, Shuohui Yang. Multi-b-value DWI to evaluate the synergistic antiproliferation and anti-heterogeneity effects of bufalin plus sorafenib in an orthotopic HCC model. European radiology experimental. 2024 Mar; 8(1):43. doi: 10.1186/s41747-024-00448-y. [PMID: 38467904]
  • Xianhua She, Donghong Yin, Qian Guo, Yang Tang, Shuyun Wang, Xuyan Wang. Electrolyte disorders induced by six multikinase inhibitors therapy for renal cell carcinoma: a large-scale pharmacovigilance analysis. Scientific reports. 2024 03; 14(1):5592. doi: 10.1038/s41598-024-56335-4. [PMID: 38454105]
  • Yulu Tan, Zijun Wang, Rui Guo, Xueru Zhou, Wei Zhang, Mengying Wu, Chenqi Guo, Huile Gao, Xun Sun, Zhirong Zhang, Tao Gong. Dual-Targeting Macrophages and Hepatic Stellate Cells by Modified Albumin Nanoparticles for Liver Cirrhosis Treatment. ACS applied materials & interfaces. 2024 Mar; 16(9):11239-11250. doi: 10.1021/acsami.3c17670. [PMID: 38395769]
  • Ting Li, Hai-Yan Huang, Bo Qian, Wei-Hua Wang, Qi Yuan, Han-Yu Zhang, Jie He, Ke-Jian Ni, Pan Wang, Zhuo-Ying Zhao, Jun-Lin He, Shi-Wei Fu, Ling Xu, Yu-Chun Lin, Zhong-Ning Lin. Interventing mitochondrial PD-L1 suppressed IFN-γ-induced cancer stemness in hepatocellular carcinoma by sensitizing sorafenib-induced ferroptosis. Free radical biology & medicine. 2024 02; 212(?):360-374. doi: 10.1016/j.freeradbiomed.2023.12.034. [PMID: 38171407]
  • Wei Liu, Shengli Wang, Lin Lin, Renlong Zou, Hongmiao Sun, Kai Zeng, Yi Wu, Yiling Li, Kato Shigeaki, Xiuxia Wang, Chunyu Wang, Yue Zhao. BAP18 acting as a novel peroxisome proliferator-activated receptor α co-regulator contributes to hepatocellular carcinoma progression. Biochimica et biophysica acta. Molecular basis of disease. 2024 Feb; 1870(2):166974. doi: 10.1016/j.bbadis.2023.166974. [PMID: 38042310]
  • Xinyue Zhang, Tianhong Su, Yifan Wu, Yuhong Cai, Lina Wang, Cong Liang, Lei Zhou, Shiyan Wang, Xiao-Xing Li, Sui Peng, Ming Kuang, Jun Yu, Lixia Xu. N6-methyladenosine reader YTHDF1 promotes stemness and therapeutic resistance in hepatocellular carcinoma by enhancing NOTCH1 expression. Cancer research. 2024 Jan; ?(?):. doi: 10.1158/0008-5472.can-23-1916. [PMID: 38241695]
  • Shi-Hui Hao, Xiao-Dan Ma, Li Xu, Jing-Dun Xie, Zi-Hao Feng, Jie-Wei Chen, Ri-Xin Chen, Feng-Wei Wang, Yu-Hao Tang, Dan Xie, Mu-Yan Cai. Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2024 Jan; 73(?):101052. doi: 10.1016/j.drup.2024.101052. [PMID: 38262246]
  • Joanna Sumorek-Wiadro, Adrian Zając, Krystyna Skalicka-Woźniak, Wojciech Rzeski, Joanna Jakubowicz-Gil. Furanocoumarins as Enhancers of Antitumor Potential of Sorafenib and LY294002 toward Human Glioma Cells In Vitro. International journal of molecular sciences. 2024 Jan; 25(2):. doi: 10.3390/ijms25020759. [PMID: 38255833]
  • Jue Li, Lusha Zhang, Teng Ge, Jiping Liu, Chuan Wang, Qi Yu. Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and Treatment Implications. Drug design, development and therapy. 2024; 18(?):829-843. doi: 10.2147/dddt.s443107. [PMID: 38524877]
  • Zhiwei Zheng, Yuxuan Lin, Hongfu Cai. Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis. Frontiers in public health. 2024; 12(?):1356244. doi: 10.3389/fpubh.2024.1356244. [PMID: 38562257]
  • Xiao-Feng He, Yun-Bao Ma, Tian-Ze Li, Ji-Jun Chen. Highly oxygenated guaiane-type sesquiterpene lactones from Artemisia sacrorum and their antihepatoma activity. Phytochemistry. 2024 Jan; 217(?):113930. doi: 10.1016/j.phytochem.2023.113930. [PMID: 37993076]
  • Pattaraporn Chaisupasakul, Dumrongsak Pekthong, Apirath Wangteeraprasert, Worasak Kaewkong, Julintorn Somran, Naphat Kaewpaeng, Supawadee Parhira, Piyarat Srisawang. Combination of ethyl acetate fraction from Calotropis gigantea stem bark and sorafenib induces apoptosis in HepG2 cells. PloS one. 2024; 19(3):e0300051. doi: 10.1371/journal.pone.0300051. [PMID: 38527038]
  • Chun Wang, Zhihang Chen, Yun Yi, Yang Ding, Fei Xu, Hui Kang, Kun Lin, Xiawen Shu, Zibiao Zhong, Zhonglin Zhang, Jing Liu, Zhong Xu, Lan Liu, Xingxing He, Ying Chang, Qiu Zhao. RBM45 reprograms lipid metabolism promoting hepatocellular carcinoma via Rictor and ACSL1/ACSL4. Oncogene. 2024 Jan; 43(5):328-340. doi: 10.1038/s41388-023-02902-4. [PMID: 38040804]
  • Qiuping Chen, Quan Sun, Jing Zhang, Baixue Li, Quansheng Feng, Jibin Liu. Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma. PloS one. 2024; 19(3):e0295090. doi: 10.1371/journal.pone.0295090. [PMID: 38437209]
  • Yu-Lian Wan, Jun-Zhi Wang, Yuan Yuan, Wang-Yang Ye, Hua-Li Li, Xiao-Lan Zhang, Hong-Qi Zhang, Li-E Li. [Trametenolic acid inhibits migration and invasion of hepatocellular carcinoma HepG2.2.15 cells via RhoC/ROCK1 pathway]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. 2024 Jan; 49(1):185-196. doi: 10.19540/j.cnki.cjcmm.20230914.703. [PMID: 38403351]
  • Zijian Wang, Chunyang Zhou, Yiming Zhang, Xinchen Tian, Haochen Wang, Jibiao Wu, Shulong Jiang. From synergy to resistance: Navigating the complex relationship between sorafenib and ferroptosis in hepatocellular carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2024 Jan; 170(?):116074. doi: 10.1016/j.biopha.2023.116074. [PMID: 38147732]
  • Kaushik Kuche, Vivek Yadav, M Dharshini, Rohan Ghadi, Dasharath Chaudhari, Tushar Date, Sanyog Jain. Synergistic anticancer therapy via ferroptosis using modified bovine serum albumin nanoparticles loaded with sorafenib and simvastatin. International journal of biological macromolecules. 2023 Dec; 253(Pt 8):127254. doi: 10.1016/j.ijbiomac.2023.127254. [PMID: 37813219]
  • Zhou Fang, Mengdi Song, Keqiang Lai, Mingxiao Cui, Mingyu Yin, Kehai Liu. Kiwi-derived extracellular vesicles for oral delivery of sorafenib. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2023 Dec; 191(?):106604. doi: 10.1016/j.ejps.2023.106604. [PMID: 37821012]
  • Omar S Sakr, Mohamed M A Zaitoun, Mohamed S Amer, Mahmoud Qubisi, Ahmed H Elshafeey, Olivier Jordan, Gerrit Borchard. Explosomes: A new modality for DEB-TACE local delivery of sorafenib: In vivo proof of sustained release. Journal of controlled release : official journal of the Controlled Release Society. 2023 12; 364(?):12-22. doi: 10.1016/j.jconrel.2023.10.013. [PMID: 37816482]
  • Yuki Kojima, Mamoru Tanaka, Makiko Sasaki, Keiji Ozeki, Takaya Shimura, Eiji Kubota, Hiromi Kataoka. Induction of ferroptosis by photodynamic therapy and enhancement of antitumor effect with ferroptosis inducers. Journal of gastroenterology. 2023 Nov; ?(?):. doi: 10.1007/s00535-023-02054-y. [PMID: 37947872]
  • Hai-Hua Wang, Song-Qing Fan, Yu-Ting Zhan, Shu-Ping Peng, Wei-Yuan Wang. Suppression of the SLC7A11/glutathione axis causes ferroptosis and apoptosis and alters the mitogen-activated protein kinase pathway in nasopharyngeal carcinoma. International journal of biological macromolecules. 2023 Nov; ?(?):127976. doi: 10.1016/j.ijbiomac.2023.127976. [PMID: 37951442]
  • Haiyan Du, Haochen Wu, Qinyang Kang, Mianmian Liao, Meirong Qin, Ning Chen, Houshuang Huang, Danping Huang, Ping Wang, Guangdong Tong. Polyphyllin I attenuates the invasion and metastasis via downregulating GRP78 in drug-resistant hepatocellular carcinoma cells. Aging. 2023 Nov; 15(?):. doi: 10.18632/aging.205176. [PMID: 37934581]
  • Ye Yuan, Chunyu Tian, Qi Wang, Xinyu Qiu, Yufang Wang, Hulin Jiang, Jifu Hao, Yujing He. Synergistic Amplification of Ferroptosis with Liposomal Oxidation Catalyst and Gpx4 Inhibitor for Enhanced Cancer Therapy. Advanced healthcare materials. 2023 11; 12(28):e2301292. doi: 10.1002/adhm.202301292. [PMID: 37458333]
  • Weimin Zhong, Huijing Chen, Jiayi Yang, Chaoqun Huang, Yao Lin, Jiyi Huang. Inflammatory response-based prognostication and personalized therapy decisions in clear cell renal cell cancer to aid precision oncology. BMC medical genomics. 2023 10; 16(1):265. doi: 10.1186/s12920-023-01687-5. [PMID: 37885006]
  • Jin Lei, Shenwu Zhang, Zehua Wu, Xinxin Sun, Binghong Zhou, Peiqi Huang, Mingzhu Fang, Lin Li, Cong Luo, Zhonggui He. Self-engineered binary nanoassembly enabling closed-loop glutathione depletion-amplified tumor ferroptosis. Biomaterials science. 2023 Oct; ?(?):. doi: 10.1039/d3bm01153d. [PMID: 37791561]
  • Man-Ru Liu, Ce Shi, Qiu-Ya Song, Meng-Jie Kang, Xin Jiang, Hui Liu, Dong-Sheng Pei. Sorafenib induces ferroptosis by promoting TRIM54-mediated FSP1 ubiquitination and degradation in hepatocellular carcinoma. Hepatology communications. 2023 10; 7(10):. doi: 10.1097/hc9.0000000000000246. [PMID: 37695069]
  • Kai Zeng, Qinyu Li, Guoda Song, Bingliang Chen, Min Luo, Jianping Miao, Bo Liu. CPT2-mediated fatty acid oxidation inhibits tumorigenesis and enhances sorafenib sensitivity via the ROS/PPARγ/NF-κB pathway in clear cell renal cell carcinoma. Cellular signalling. 2023 10; 110(?):110838. doi: 10.1016/j.cellsig.2023.110838. [PMID: 37541641]
  • Jia-Xin Yan, Qi-Hao Li, Tian-Ze Li, Zhi-Yan Huang, Yun-Bao Ma, Ji-Jun Chen. Design and synthesis of guaianolide-germacranolide heterodimers as novel anticancer agents against hepatocellular carcinoma. Drug development research. 2023 09; 84(6):1285-1298. doi: 10.1002/ddr.22087. [PMID: 37345274]
  • Tian-Jiao Zhou, Xing Wan, Meng-Meng Zhang, Dan-Meng Liu, Li-Ling Huang, Lei Xing, Yi Wang, Hu-Lin Jiang. Tumor microenvironment-initiated lipid redox cycling for efficient triple-negative breast cancer therapy. Biomaterials. 2023 09; 300(?):122205. doi: 10.1016/j.biomaterials.2023.122205. [PMID: 37348324]
  • Junyi Wu, Xiangjie Xu, Shasha Wu, Weiwei Shi, Guang Zhang, Yin Cao, Zhongxia Wang, Junhua Wu, Chunping Jiang. UBE2S promotes malignant properties via VHL/HIF-1α and VHL/JAK2/STAT3 signaling pathways and decreases sensitivity to sorafenib in hepatocellular carcinoma. Cancer medicine. 2023 Aug; ?(?):. doi: 10.1002/cam4.6431. [PMID: 37563971]
  • Tung-Wei Hsu, Yen-Hao Su, Hsin-An Chen, Po-Hsiang Liao, Shih Chiang Shen, Kuei-Yen Tsai, Tzu-Hsuan Wang, Alvin Chen, Chih-Yang Huang, Marthandam Asokan Shibu, Wan-Yu Wang, Shing-Chuan Shen. Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis. Aging. 2023 07; 15(13):6503-6525. doi: 10.18632/aging.204867. [PMID: 37433225]
  • Yingying Chen, Huan Tao, Fujue Wang, Pengqiang Wu, Jie Gao, Xue Zhang, Zhengcang He, Zhencang Zhou, Yongqian Jia. Artesunate synergistically promotes sorafenib‑induced apoptosis and ferroptosis in non‑Hodgkin lymphoma cells through inhibition of the STAT3 pathway. Oncology reports. 2023 Jul; 50(1):. doi: 10.3892/or.2023.8584. [PMID: 37326033]
  • Abdulmajeed Bahman, Mohamed-Salah Abaza, Sarah Khoushaish, Rajaa J Al-Attiyah. Therapeutic efficacy of sorafenib and plant-derived phytochemicals in human colorectal cancer cells. BMC complementary medicine and therapies. 2023 Jun; 23(1):210. doi: 10.1186/s12906-023-04032-6. [PMID: 37365571]
  • Zongqiang Hu, Yingpeng Zhao, Laibang Li, Jie Jiang, Wang Li, Yuanyi Mang, Yang Gao, Yun Dong, Jiashun Zhu, Chaomin Yang, Jianghua Ran, Li Li, Shengning Zhang. Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3. Molecular biology reports. 2023 Jun; ?(?):. doi: 10.1007/s11033-023-08492-4. [PMID: 37326750]
  • Christian Bergamini, Ilaria Leoni, Nicola Rizzardi, Mattia Melli, Giuseppe Galvani, Camelia Alexandra Coada, Catia Giovannini, Elisa Monti, Irene Liparulo, Francesca Valenti, Manuela Ferracin, Matteo Ravaioli, Matteo Cescon, Francesco Vasuri, Fabio Piscaglia, Massimo Negrini, Claudio Stefanelli, Romana Fato, Laura Gramantieri, Francesca Fornari. MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma. Journal of experimental & clinical cancer research : CR. 2023 Jun; 42(1):145. doi: 10.1186/s13046-023-02718-w. [PMID: 37301960]
  • Tian-Ze Li, Xiao-Tong Yang, Wen-Jing Ma, Yun-Bao Ma, Feng-Jiao Li, Yong-Cui Wang, Ji-Jun Chen. Design, synthesis, and biological evaluation of artemyrianolide H derivatives as potential antihepatoma agents. Bioorganic chemistry. 2023 May; 137(?):106617. doi: 10.1016/j.bioorg.2023.106617. [PMID: 37267793]
  • Ziwen Li, Xinyi Liao, Yameng Hu, Man Li, Miaoling Tang, Shuxia Zhang, Shuang Mo, Xincheng Li, Suwen Chen, Wanying Qian, Rongni Feng, Ruyuan Yu, Yingru Xu, Shuanghu Yuan, Chan Xie, Jun Li. SLC27A4-mediated selective uptake of mono-unsaturated fatty acids promotes ferroptosis defense in hepatocellular carcinoma. Free radical biology & medicine. 2023 05; 201(?):41-54. doi: 10.1016/j.freeradbiomed.2023.03.013. [PMID: 36924851]
  • Ahmed S Elkateb, Shahira Nofal, Sahar A Ali, Hanaa B Atya. Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2. Inflammation. 2023 May; ?(?):. doi: 10.1007/s10753-023-01823-4. [PMID: 37171695]
  • Yinglan Yu, Xinran Shen, Xin Xiao, Lian Li, Yuan Huang. Butyrate Modification Promotes Intestinal Absorption and Hepatic Cancer Cells Targeting of Ferroptosis Inducer Loaded Nanoparticle for Enhanced Hepatocellular Carcinoma Therapy. Small (Weinheim an der Bergstrasse, Germany). 2023 May; ?(?):e2301149. doi: 10.1002/smll.202301149. [PMID: 37165608]
  • Zelong Gao, Dongyao Wang, Jianxin Yang, Min Li, Changquan Ling, Diya Lv, Yan Cao, Zhenyu Chen, Ce Shi, Hui Shen, Yuxiao Tang. Iron deficiency in hepatocellular carcinoma cells induced sorafenib resistance by upregulating HIF-1α to inhibit apoptosis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2023 Apr; 163(?):114750. doi: 10.1016/j.biopha.2023.114750. [PMID: 37087978]
  • Huan Wang, Yiming Wang, Jiongyuan Li, Ziyi He, Sarah A Boswell, Mirra Chung, Fuping You, Sen Han. Three tyrosine kinase inhibitors cause cardiotoxicity by inducing endoplasmic reticulum stress and inflammation in cardiomyocytes. BMC medicine. 2023 04; 21(1):147. doi: 10.1186/s12916-023-02838-2. [PMID: 37069550]
  • Yanqiu Xie, Shijie Fan, Dongxuan Ni, Wei Wan, Pan Xu, Yiluan Ding, Ruihan Zhang, Jing Lu, Naixia Zhang, Yuanyuan Zhang, Weilie Xiao, Kehao Zhao, Cheng Luo. An ATG4B inhibitor blocks autophagy and sensitizes Sorafenib inhibition activities in HCC tumor cells. Bioorganic & medicinal chemistry. 2023 04; 84(?):117262. doi: 10.1016/j.bmc.2023.117262. [PMID: 37018878]
  • Homa Fatma, Mohd Jameel, Kafil Akhtar, Mairaj Ahmed Ansari, Hifzur R Siddique. Implication of Lupeol in compensating Sorafenib-induced perturbations of redox homeostasis: A preclinical study in mouse model. Life sciences. 2023 Apr; ?(?):121647. doi: 10.1016/j.lfs.2023.121647. [PMID: 37011877]
  • Yanhong Sun, Xiaoyan Duan, Fenghe Wang, Huixin Tan, Jiahuan Hu, Wanting Bai, Xinbo Wang, Baolian Wang, Jinping Hu. Inhibitory effects of flavonoids on glucose transporter 1 (GLUT1): From library screening to biological evaluation to structure-activity relationship. Toxicology. 2023 Mar; ?(?):153475. doi: 10.1016/j.tox.2023.153475. [PMID: 36870413]
  • Lu Zhang, Xian-Meng Li, Xu-He Shi, Kai Ye, Xue-Li Fu, Xue Wang, Shi-Man Guo, Jia-Qi Ma, Fei-Fei Xu, Hui-Min Sun, Qian-Qian Li, Wei-Ying Zhang, Li-Hong Ye. Sorafenib triggers ferroptosis via inhibition of HBXIP/SCD axis in hepatocellular carcinoma. Acta pharmacologica Sinica. 2023 Mar; 44(3):622-634. doi: 10.1038/s41401-022-00981-9. [PMID: 36109580]
  • Yao Chen, Dong Zhao, Feng Xiao, Xuanyu Li, Jia'an Li, Zhenwei Su, Xingyu Jiang. Microfluidics-enabled Serial Assembly of Lipid-siRNA-sorafenib Nanoparticles for Synergetic Hepatocellular Carcinoma Therapy. Advanced materials (Deerfield Beach, Fla.). 2023 Mar; 35(13):e2209672. doi: 10.1002/adma.202209672. [PMID: 36749980]
  • Davide Gnocchi, Carlo Sabbà, Antonio Mazzocca. Crithmum maritimum Improves Sorafenib Sensitivity by Decreasing Lactic Acid Fermentation and Inducing a Pro-Hepatocyte Marker Profile in Hepatocellular Carcinoma. Plant foods for human nutrition (Dordrecht, Netherlands). 2023 Mar; 78(1):230-232. doi: 10.1007/s11130-022-01037-3. [PMID: 36525173]
  • Chen Yang, Tao Lu, Ming Liu, Xiaoqing Yuan, Desheng Li, Jiayu Zhang, Ling Zhou, Maolei Xu. Tiliroside targets TBK1 to induce ferroptosis and sensitize hepatocellular carcinoma to sorafenib. Phytomedicine : international journal of phytotherapy and phytopharmacology. 2023 Mar; 111(?):154668. doi: 10.1016/j.phymed.2023.154668. [PMID: 36657316]
  • Jingyang Su, Jinhua Lu, Jialin Zhang, Menglei Wang, Jiang Yan, Shengyou Lin. A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately?. Current opinion in oncology. 2023 03; 35(2):132-144. doi: 10.1097/cco.0000000000000924. [PMID: 36721897]
  • Xiaorui Wang, Lei Zhao, Chenxi Wang, Leichen Wang, Haisi Wu, Xuejiao Song, Wenjun Wang, Huae Xu, Xiaochen Dong. Potent nanoreactor-mediated ferroptosis-based strategy for the reversal of cancer chemoresistance to Sorafenib. Acta biomaterialia. 2023 Feb; ?(?):. doi: 10.1016/j.actbio.2023.01.053. [PMID: 36736851]
  • Xuetian Yue, Youzi Kong, Yankun Zhang, Min Sun, Shuyue Liu, Zhuanchang Wu, Lifen Gao, Xiaohong Liang, Chunhong Ma. SREBF2-STARD4 axis confers sorafenib resistance in hepatocellular carcinoma by regulating mitochondrial cholesterol homeostasis. Cancer science. 2023 Feb; 114(2):477-489. doi: 10.1111/cas.15449. [PMID: 35642354]
  • Feng-Li Xu, Xiao-Hong Wu, Chang Chen, Kai Wang, Lu-Yi Huang, Jie Xia, Yi Liu, Xue-Feng Shan, Ni Tang. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase. Cell death & disease. 2023 Jan; 14(1):22. doi: 10.1038/s41419-023-05558-w. [PMID: 36635256]
  • Yan Li, Wenjuan Yang, Yuanyuan Zheng, Weiqi Dai, Jie Ji, Liwei Wu, Ziqi Cheng, Jie Zhang, Jingjing Li, Xuanfu Xu, Jianye Wu, Mingwei Yang, Jiao Feng, Chuanyong Guo. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. Journal of experimental & clinical cancer research : CR. 2023 Jan; 42(1):6. doi: 10.1186/s13046-022-02567-z. [PMID: 36604718]
  • Yanhong Su, Zhao Zhang, Leo Tsz On Lee, Ling Peng, Ligong Lu, Xu He, Xuanjun Zhang. Amphiphilic Dendrimer Doping Enhanced pH-Sensitivity of Liposomal Vesicle for Effective Co-delivery toward Synergistic Ferroptosis-Apoptosis Therapy of Hepatocellular Carcinoma. Advanced healthcare materials. 2023 01; 12(6):e2202663. doi: 10.1002/adhm.202202663. [PMID: 36653312]
  • Xiaoming Li, Yunhui Li, Peilong Lian, Qigang Lv, Fangfeng Liu. Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by adsorbing miR-450b-5p to avert sorafenib resistance in hepatocellular carcinoma. Human & experimental toxicology. 2023 Jan; 42(?):9603271221142818. doi: 10.1177/09603271221142818. [PMID: 36786348]
  • Hao Jiang, Jian Liao, Liezhi Wang, Chong Jin, Jinggang Mo, Sheng Xiang. The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms. Frontiers in immunology. 2023; 14(?):1163967. doi: 10.3389/fimmu.2023.1163967. [PMID: 37325670]
  • Can-Can Zhou, Yu-Qiong He, Yu-Shuang Qiu, Chen-Xu Ni, Fu-Ming Shen, Dong-Jie Li. Zinc supplementation ameliorates sorafenib-induced cognitive impairment through ROS/JNK signaling pathway. Biological trace element research. 2023 Jan; 201(1):324-337. doi: 10.1007/s12011-022-03142-5. [PMID: 35129807]
  • Ruiqi Liu, Yingyi Liu, Fengyue Zhang, Jinrui Wei, Lichuan Wu. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma. Frontiers in immunology. 2023; 14(?):1146411. doi: 10.3389/fimmu.2023.1146411. [PMID: 37063920]
  • Ling Wang, Jin Wang, Ling Chen. TIMP1 represses sorafenib-triggered ferroptosis in colorectal cancer cells by activating the PI3K/Akt signaling pathway. Immunopharmacology and immunotoxicology. 2022 Dec; ?(?):1-19. doi: 10.1080/08923973.2022.2160731. [PMID: 36541209]
  • Linzhou Yin, Pengyu Liu, Yue Jin, Zunxi Ning, Yiren Yang, Huiyuan Gao. Ferroptosis-related small-molecule compounds in cancer therapy: Strategies and applications. European journal of medicinal chemistry. 2022 Dec; 244(?):114861. doi: 10.1016/j.ejmech.2022.114861. [PMID: 36332549]
  • Qing Luo, Jingjing Yang, Haohang Xu, Jieran Shi, Zhen Liang, Rui Zhang, Ping Lu, Guojuan Pu, Ningmin Zhao, Junjie Zhang. Sorafenib-loaded nanostructured lipid carriers for topical ocular therapy of corneal neovascularization: development, in-vitro and in vivo study. Drug delivery. 2022 Dec; 29(1):837-855. doi: 10.1080/10717544.2022.2048134. [PMID: 35277107]
  • Yi Yu, Yuanyuan Ren, Caihua Wang, Zhuozhuo Li, Fanglin Niu, Zi Li, Qiang Ye, Jiangxia Wang, Yuan Yan, Ping Liu, Lu Qian, Yuyan Xiong. Arginase 2 negatively regulates sorafenib-induced cell death by mediating ferroptosis in melanoma. Acta biochimica et biophysica Sinica. 2022 Nov; 54(11):1658-1670. doi: 10.3724/abbs.2022166. [PMID: 36604146]
  • Suzan Abdu, Nouf Juaid, Amr Amin, Mohamed Moulay, Nabil Miled. Effects of Sorafenib and Quercetin Alone or in Combination in Treating Hepatocellular Carcinoma: In Vitro and In Vivo Approaches. Molecules (Basel, Switzerland). 2022 Nov; 27(22):. doi: 10.3390/molecules27228082. [PMID: 36432184]
  • Dong-Ho Kim, Mi-Jin Kim, Na-Young Kim, Seunghyeong Lee, Jun-Kyu Byun, Jae Won Yun, Jaebon Lee, Jonghwa Jin, Jina Kim, Jungwook Chin, Sung Jin Cho, In-Kyu Lee, Yeon-Kyung Choi, Keun-Gyu Park. DN200434, an orally available inverse agonist of estrogen-related receptor γ, induces ferroptosis in sorafenib-resistant hepatocellular carcinoma. BMB reports. 2022 Nov; 55(11):547-552. doi: . [PMID: 36016501]
  • Ming Bai, Wei Xu, Qian Li, De-Feng Liu, Tian-Ming Lv, Ning-Ning Du, Guo-Dong Yao, Bin Lin, Shao-Jiang Song, Xiao-Xiao Huang. Highly Oxidized Germacranolides from Elephantopus tomentosus and the Configurational Revision of Some Previously Reported Analogues. Journal of natural products. 2022 10; 85(10):2433-2444. doi: 10.1021/acs.jnatprod.2c00630. [PMID: 36223633]
  • Yidan Lai, Nong Lu, Shuangling Luo, Haobing Wang, Pingyu Zhang. A Photoactivated Sorafenib-Ruthenium(II) Prodrug for Resistant Hepatocellular Carcinoma Therapy through Ferroptosis and Purine Metabolism Disruption. Journal of medicinal chemistry. 2022 10; 65(19):13041-13051. doi: 10.1021/acs.jmedchem.2c00880. [PMID: 36134739]
  • Chunmei Chen, Yixin Tan, Ting Xu, Yihao Sun, Sheng Zhao, Yi Ouyang, Yan Chen, Liang He, Xiaohong Liu, Hui Liu. Sorafenib-Loaded Copper Peroxide Nanoparticles with Redox Balance Disrupting Capacity for Enhanced Chemodynamic Therapy against Tumor Cells. Langmuir : the ACS journal of surfaces and colloids. 2022 10; 38(40):12307-12315. doi: 10.1021/acs.langmuir.2c01938. [PMID: 36154182]
  • Xiaojing Du, Zhuoran Qi, Jinzhi Xu, Mengzhou Guo, Xingxing Zhang, Zhijie Yu, Xin Cao, Jinglin Xia. Loss of GABARAPL1 confers ferroptosis resistance to cancer stem-like cells in hepatocellular carcinoma. Molecular oncology. 2022 10; 16(20):3703-3719. doi: 10.1002/1878-0261.13305. [PMID: 36062307]
  • Jialiang Luo, Lei Li, Zhengyumeng Zhu, Bo Chang, Fan Deng, Di Wang, Xiao Lu, Daming Zuo, Qingyun Chen, Jia Zhou. Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022 Oct; 154(?):113602. doi: 10.1016/j.biopha.2022.113602. [PMID: 36029544]
  • Shou-Sen Huang, Chung-Hsin Tsai, Chi-Yu Kuo, Ying-Syuan Li, Shih-Ping Cheng. ACLY inhibitors induce apoptosis and potentiate cytotoxic effects of sorafenib in thyroid cancer cells. Endocrine. 2022 10; 78(1):85-94. doi: 10.1007/s12020-022-03124-6. [PMID: 35761130]
  • Chao-Yuan Huang, Li-Ju Chen, Grace Chen, Tzu-I Chao, Cheng-Yi Wang. SHP-1/STAT3-Signaling-Axis-Regulated Coupling between BECN1 and SLC7A11 Contributes to Sorafenib-Induced Ferroptosis in Hepatocellular Carcinoma. International journal of molecular sciences. 2022 Sep; 23(19):. doi: 10.3390/ijms231911092. [PMID: 36232407]
  • Wataru Jomen, Takaaki Ohtake, Takayuki Akita, Daisuke Suto, Hideki Yagi, Yosuke Osawa, Yutaka Kohgo. Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022 Sep; 153(?):113363. doi: 10.1016/j.biopha.2022.113363. [PMID: 35834989]
  • Hui Jiang, Cong Wang, An Zhang, Yufeng Li, Jianping Li, Zhan Li, Xin Yang, Yinglong Hou. ATF4 protects against sorafenib-induced cardiotoxicity by suppressing ferroptosis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2022 Sep; 153(?):113280. doi: 10.1016/j.biopha.2022.113280. [PMID: 35724508]
  • Wenjie Feng, Wanrui Shi, Ze Wang, Yanqi Cui, Xinxin Shao, Shuwei Liu, Li Rong, Yi Liu, Hao Zhang. Enhancing Tumor Therapy of Fe(III)-Shikonin Supramolecular Nanomedicine via Triple Ferroptosis Amplification. ACS applied materials & interfaces. 2022 Aug; 14(33):37540-37552. doi: 10.1021/acsami.2c11130. [PMID: 35944147]
  • Li Zhou, Yiqiang Liu, Jiazhi Mo, Chuanliang Cui, Zhihong Chi, Lu Si, Yan Kong, Xieqiao Yan, Siming Li, Xiaowen Wu, Juan Li, Huayan Xu, Dengfeng Cao, Jun Guo, Xinan Sheng. Clinicopathological characteristics and prognosis of metastatic collecting duct carcinoma. Urologic oncology. 2022 Aug; 40(8):385.e1-385.e8. doi: 10.1016/j.urolonc.2022.05.014. [PMID: 35773144]
  • Wei Qin, Li Wang, Huan Tian, Xiaocai Wu, Cuicui Xiao, Yuhang Pan, Mingming Fan, Yan Tai, Wei Liu, Qi Zhang, Yang Yang. CAF-derived exosomes transmitted Gremlin-1 promotes cancer progression and decreases the sensitivity of hepatoma cells to sorafenib. Molecular carcinogenesis. 2022 08; 61(8):764-775. doi: 10.1002/mc.23416. [PMID: 35638711]
  • Han Li, You Yu, Yi Liu, Zhihong Luo, Betty Yuen Kwan Law, Yi Zheng, Xing Huang, Wenhua Li. Ursolic acid enhances the antitumor effects of sorafenib associated with Mcl-1-related apoptosis and SLC7A11-dependent ferroptosis in human cancer. Pharmacological research. 2022 08; 182(?):106306. doi: 10.1016/j.phrs.2022.106306. [PMID: 35714823]
  • Deepti Singh, Mohammad Afsar Khan, Kafil Akhtar, Farukh Arjmand, Hifzur R Siddique. Apigenin alleviates cancer drug Sorafenib induced multiple toxic effects in Swiss albino mice via anti-oxidative stress. Toxicology and applied pharmacology. 2022 07; 447(?):116072. doi: 10.1016/j.taap.2022.116072. [PMID: 35613639]
  • Bao Guo, Xiaoyan Xu, Miaomiao Shao, Xu Yang, Gaofei He, Kangwei Qi, Jianxin Gu, Lan Wang. UDP-glucose 6-dehydrogenase lessens sorafenib sensitivity via modulating unfolded protein response. Biochemical and biophysical research communications. 2022 07; 613(?):207-213. doi: 10.1016/j.bbrc.2022.05.048. [PMID: 35617808]
  • Clément Carbasse, Fanny Leenhardt, William Jacot, Caroline Perrier, Frederic Pinguet, Marie Viala. Oral targeted therapy dose adaptation in older patients with cancer: A real-life French cohort. British journal of clinical pharmacology. 2022 07; 88(7):3370-3377. doi: 10.1111/bcp.15285. [PMID: 35178745]
  • Anne-Rose W Schut, Anne L M Vriends, Andrea Sacchetti, Milea J M Timbergen, Benjamin A Alman, Mushriq Al-Jazrawe, Dirk J Grünhagen, Cornelis Verhoef, Stefan Sleijfer, Erik A C Wiemer. In desmoid-type fibromatosis cells sorafenib induces ferroptosis and apoptosis, which are enhanced by autophagy inhibition. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2022 07; 48(7):1527-1535. doi: 10.1016/j.ejso.2022.02.020. [PMID: 35221159]
  • Maohua Huang, Yuning Lin, Chenran Wang, Lijuan Deng, Minfeng Chen, Yehuda G Assaraf, Zhe-Sheng Chen, Wencai Ye, Dongmei Zhang. New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy. 2022 Jun; 64(?):100849. doi: 10.1016/j.drup.2022.100849. [PMID: 35842983]
  • Tengfei Liu, Junming Yu, Chao Ge, Fangyu Zhao, Jing Chen, Chunxiao Miao, Wenjiao Jin, Qingqing Zhou, Qin Geng, Hechun Lin, Hua Tian, Taoyang Chen, Haiyang Xie, Ying Cui, Ming Yao, Xiuying Xiao, Jinjun Li, Hong Li. Sperm associated antigen 4 promotes SREBP1-mediated de novo lipogenesis via interaction with lamin A/C and contributes to tumor progression in hepatocellular carcinoma. Cancer letters. 2022 06; 536(?):215642. doi: 10.1016/j.canlet.2022.215642. [PMID: 35307486]
  • Jessica A Pollard, Todd A Alonzo, Robert Gerbing, Patrick Brown, Elizabeth Fox, John Choi, Brian Fisher, Betsy Hirsch, Samir Kahwash, Kelly Getz, John Levine, Lisa Eidenschink Brodersen, Michael R Loken, Susana Raimondi, Katherine Tarlock, Andrew Wood, Lillian Sung, E Anders Kolb, Alan Gamis, Soheil Meshinchi, Richard Aplenc. Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Jun; 40(18):2023-2035. doi: 10.1200/jco.21.01612. [PMID: 35349331]
  • Andrew J Smith, Prashant Ruchaya, Robert Walmsley, Kathleen E Wright, Fiona C Lewis-McDougall, Jacquelyn Bond, Georgina M Ellison-Hughes. Receptor tyrosine kinase inhibitors negatively impact on pro-reparative characteristics of human cardiac progenitor cells. Scientific reports. 2022 Jun; 12(1):10132. doi: 10.1038/s41598-022-13203-3. [PMID: 35710779]
  • Xue Deng, Xueyan Li, Xuan Guo, Yantong Lu, Yingjie Xie, Xuhui Huang, Juze Lin, Wei Tan, Changjun Wang. Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis. Neoplasia (New York, N.Y.). 2022 06; 28(?):100788. doi: 10.1016/j.neo.2022.100788. [PMID: 35378464]
  • Hui-Teng Cheng, Hsi-Chien Huang, Tsung-Ying Lee, Yu-Hui Liao, Yi-Hua Sheng, Pei-Ru Jin, Kuan-Wei Huang, Ling-Hsuan Chen, Yi-Ting Chen, Zi-Yan Liu, Tzu-Chieh Lin, Hsueh-Cheng Wang, Cheng-Han Chao, I Pu Juang, Chi-Ting Su, Kuo-How Huang, Shuei-Liong Lin, Jane Wang, Yun-Chieh Sung, Yunching Chen. Delivery of sorafenib by myofibroblast-targeted nanoparticles for the treatment of renal fibrosis. Journal of controlled release : official journal of the Controlled Release Society. 2022 Jun; 346(?):169-179. doi: 10.1016/j.jconrel.2022.04.004. [PMID: 35429575]
  • Mototsugu Oya, Shuichi Kaneko, Tsuneo Imai, Toshiaki Tsujino, Toshiyuki Sunaya, Yutaka Okayama. Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment. Cancer chemotherapy and pharmacology. 2022 Jun; 89(6):761-772. doi: 10.1007/s00280-022-04428-0. [PMID: 35445315]
  • Jose A Karam, Maneka Puligandla, Keith T Flaherty, Robert G Uzzo, Surena F Matin, Michael R Pins, Christopher G Wood, Christopher Kane, Michael A S Jewett, Se Eun Kim, Janice P Dutcher, Robert S DiPaola, Naomi B Haas. Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805. BJU international. 2022 06; 129(6):718-722. doi: 10.1111/bju.15587. [PMID: 34480522]